Grants and Contributions:
Title:
Neurological, ocular and bone-marrow gene targeting therapy applications
Agreement Number:
988559
Agreement Value:
$375,000.00
Agreement Date:
Apr 1, 2022 - Mar 24, 2023
Description:
The project will involve the development of expanded Huntington's Disease gene therapy strategies, addition of retinal and bone marrow targeting capabilities, and demonstration of the delivery of alternate gene editing cargos.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Vancouver, British Columbia, CA V6S 1Z3
Reference Number:
172-2022-2023-Q1-988559
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
758555288
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The total amended value is 75,000 dollars.
Amendment Date
Aug 25, 2022
Recipient's Legal Name:
Incisive Genetics Inc.
Federal Riding Name:
Vancouver Quadra
Federal Riding Number:
59039
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
541710
Amendments: